Just a few weeks after Novartis announced it’s taken an ownership stake in Colorado’s SomaLogic, the proteomics company has raised $16.5 million, according to a regulatory filing.
Although SomaLogic’s keeping quiet on who’s invested and what it’s for, the company’s an early player in applying proteomics to the diagnostics field – and Novartis has a demonstrated interest in the field. The Swiss pharma giant has its own Center for Proteomic Chemistry, after all, and is building up a catalogue of proteomic compounds that can be eventually translated into new medications.
SomaLogic, in addition to diagnostics, does just that. Its SOMAmer reagent library, for instance, measures more than a thousand proteins, including kinases, cytokines, growth factors, protease inhibitors and hormones.
Beyond Analytics: How Sellers Dorsey is Hard-Coding Value into Medicaid Policy [Video]
How to turn analytics into actual policy outcomes.
SomaLogic has outlined its proteomics applications in a number of spaces:
Though the privately held SomaLogic has been around more than a decade, it’s raised $46.5 million since 2010.